sublingual TNX-102: Phase I started

Tonix began an open-label, Canadian Phase I trial to compare its 2.4 mg sublingual TNX-102 vs. 2.4 mg IV cyclobenzaprine and a marketed 5 mg oral cyclobenzaprine in about 24 healthy volunteers. ...